Natixis Advisors LLC Makes New $4.67 Million Investment in Medline $MDLN

Natixis Advisors LLC purchased a new position in Medline (NASDAQ:MDLN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 111,089 shares of the company’s stock, valued at approximately $4,666,000.

Other institutional investors also recently added to or reduced their stakes in the company. Sound Income Strategies LLC bought a new position in Medline in the 4th quarter worth approximately $25,000. Entrust Financial LLC bought a new stake in shares of Medline during the fourth quarter valued at approximately $26,000. NBC Securities Inc. bought a new stake in shares of Medline during the fourth quarter valued at approximately $28,000. Global Retirement Partners LLC bought a new stake in shares of Medline during the fourth quarter valued at approximately $31,000. Finally, North Star Investment Management Corp. bought a new stake in shares of Medline during the fourth quarter valued at approximately $36,000.

Wall Street Analyst Weigh In

MDLN has been the topic of a number of research reports. Barclays lowered their price objective on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Monday, June 1st. Sanford C. Bernstein lowered their price objective on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Stifel Nicolaus set a $55.00 price objective on Medline in a research report on Wednesday, February 25th. Wells Fargo & Company boosted their price objective on Medline from $42.00 to $47.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Finally, Deutsche Bank Aktiengesellschaft set a $42.00 price objective on Medline in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.54.

Medline Trading Up 0.6%

Shares of NASDAQ:MDLN opened at $33.80 on Tuesday. The company has a fifty day moving average of $41.29. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88. The company has a current ratio of 4.41, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion during the quarter. The company’s revenue was up 10.7% compared to the same quarter last year. Sell-side analysts predict that Medline will post 1.51 EPS for the current year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.